Abbott's new Dx platform quickly spots life-threatening infections; Lupus biomarker project begins;

> Abbott ($ABT) said promising early results indicate its new diagnostic testing platform can spot life-threatening infections more quickly than current standards of care. Release

> The Broad Institute confirmed it is laying off 27 people as the National Institutes of Health stops funding for a program that created service centers to run chemical screens for laboratories nationally. Story (reg. req.)

> Veracyte ($VCYT) is rolling out a product designed to help enhance the effectiveness and use of its Afirma thyroid cancer test. Release

> Minnesota's MGC Diagnostics ($MGCD) will distribute sleep apnea diagnostic products made by Neurovirtual USA. Release

> CT texture analysis works as an imaging biomarker to help predict the survival of metastatic melanoma patients getting antiangiogenic therapy, according to a new study. Story (reg. req.)

> Berg and the Medical University of South Carolina will collaborate to discover a new lupus biomarker. Release

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.